Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | MGAM | O43451 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SI | P14410 | 1/20 | 0.39 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6483909 | 0.82 | KMT2A (0.41) | KMT2AALDH1A1MGAMGAASI | |
| SCHEMBL15876257 | 0.81 | KMT2A (0.42) | KMT2AALDH1A1MGAMGAASI | |
| SCHEMBL11094400 | 0.81 | KMT2A (0.40) | KMT2AALDH1A1MGAMGAASI | |
| SCHEMBL27863456 | 0.79 | KMT2A (0.39) | KMT2AALDH1A1MGAMGAASI | |
| SCHEMBL3649459 | 0.79 | KMT2A (0.39) | KMT2AALDH1A1MGAMGAASI | |
| SCHEMBL28100711 | 0.79 | KMT2A (0.39) | KMT2AALDH1A1MGAMGAASI | |
| SCHEMBL901251 | 0.79 | KMT2A (0.39) | KMT2AALDH1A1MGAMGAASI | |
| SCHEMBL10028033 | 0.78 | ALDH1A1 (0.38) | KMT2AALDH1A1THRBATML3MBTL1 | |
| SCHEMBL1245725 | 0.77 | KMT2A (0.37) | KMT2AALDH1A1MGAMGAASI | |
| SCHEMBL9797015 | 0.76 | ALDH1A1 (0.38) | KMT2AALDH1A1MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020161030-A1 | Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes | HOECHST MARION ROUSSEL | 2002-10-31 | — | — | US | disclosed |
| US-6420341-B1 | TREATING VASOCONSTRICTOR AND HYPERTENSION EFFECTS IN WARM-BLOODED ANIMALS | AVENTIS PHARMA S.A. (FR) | 2002-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161030-A1 | Sulpur derivatives containing a retroamide bond as inhibitors of endothelin-converting enzymes | EDNRA, ECE1, EDNRB | KMT2A 2735/4885ALDH1A1 553/4885MGAM 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.